Elevated RIPK2 Expression in Atopic Dermatitis Skin Is Associated with Mixed Th1/Th2 Cytokine Responses in CD4

Raeda Mubariki, Ziad Khamaysi, Elie Kaabour, Mishlab Salih, Tal Belity, Elias Toubi, Eran Blacher, Zahava Vadasz

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Raeda MubarikiProteomic Unit, Bnai-Zion Medical Center, Haifa 3339419, Israel.

Ziad KhamaysiDepartment of Dermatology, Rambam Medical Campus, The Rappaport Faculty of Medicine, Haifa 3525433, Israel.ORCID 0000-0001-9586-2807

Elie KaabourDepartment of Dermatology, Rambam Medical Campus, The Rappaport Faculty of Medicine, Haifa 3525433, Israel.

Mishlab SalihDepartment of Dermatology, Rambam Medical Campus, The Rappaport Faculty of Medicine, Haifa 3525433, Israel.

Tal BelityDepartment of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Edmond J. Safra Campus Givat-Ram, Jerusalem 9190401, Israel.

Elias ToubiAllergy and Clinical Immunology, The Holy Family Hospital, Nazareth 1600934, Israel.

Eran BlacherDepartment of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Edmond J. Safra Campus Givat-Ram, Jerusalem 9190401, Israel.ORCID 0000-0003-3207-0153

Zahava VadaszProteomic Unit, Bnai-Zion Medical Center, Haifa 3339419, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Receptor-interacting protein kinase 2 (RIPK2) is a critical mediator of the immune system leading to production of pro-inflammatory cytokines. Its role in the pathogenesis of atopic dermatitis (AD) has not been defined. This work aims to assess RIPK2 expression in the skin in AD and to evaluate the association with Th1-, Th2-, and Th17-related cytokine expression in lesional skin. AD patients' skin biopsies and healthy controls were collected. An OPAL multiplex immunohistochemistry method was used to simultaneously detect TNF-α, IL-4, IL-13 and IL-17 in CD4

Indexed as

CD4-Positive T-LymphocytesCytokinesDermatitis, AtopicReceptor-Interacting Protein Serine-Threonine Kinase 2SkinTh1 CellsTh2 CellsAdultFemaleHumansMaleYoung AdultCytokinesReceptor-Interacting Protein Serine-Threonine Kinase 2RIPK2 protein, humanatopic dermatitisCD4 T cellsimmunopathogenesisRIPK2Th1/Th2 cytokines

Identifiers

PMID42794681

DOI10.3390/ijms27188253

PMCPMC13607851

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.